A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Adult Patients with Hemophilia B

Estado	**Tipo de Participantes**	**Rangos de Edad**
Reclutando	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Hombres	Fase I , Fase II	78
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	Si
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	seguridad, eficacia	Terapia génica

Información

Identificador
2023-507260-40-00 (CTIS)

Cod. Protocolo
R131L1265-HEMB-2318

Área terapéutica
Enfermedades [C] - Anormalidades congénitas, hereditarias y neonatología [C16]|

Enfermedad investigada
Hemophilia B

Título Científico
A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B

Justificación

No aportado

Objetivo Principal

Part 1: To evaluate the safety and tolerability of a single IV administration of REGV131-LNP1265 in participants with hemophilia B.
To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B to establish the recommended dose for further development
Part 2A: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B receiving the recommended dose for expansion (RDE). To assess the bleeding event rate (all bleeding events) following a single IV administration of REGV131-LNP1265 at the RDE
Long-term Follow Up (LTFU) Period: To evaluate the long-term safety of a single IV administration of REGV131-LNP1265 in participants with hemophilia B

Variables de Evaluación Primaria

Part 1: Occurrence and severity of Treatment-Emergent Adverse Events (TEAEs).
Part 1: Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assay.
Part 2A: Change from baseline in FIX functional activity in plasma after REGV131-LNP1265 dosing at the recommended dose for expansion (RDE) measured using the chromogenic substrate assay.
Part 2A: Annualized Bleeding Rate (ABR) following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving RDE.
LTFU Period: Occurrence and severity of Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and clinically meaningful Adverse Events (AEs).

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Part 1: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B receiving the RDE.
Part 1 and LTFU Period: To assess the bleeding event rate (all bleeding events) following a single IV administration of REGV131-LNP1265 at the RDE.
Part 1 and LTFU Period: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B
Part 1: To assess the bleeding event rate for bleeding events that require treatment with FIX replacement therapy following a single IV administration of REGV131-LNP1265 at the RDE.
Part 1 and LTFU Period: To evaluate FIX replacement therapy use following a single IV administration of REGV131-LNP1265 at the RDE, excluding FIX replacement for invasive procedures
Part 2A: To evaluate the safety and tolerability of a single IV administration of REGV131-LNP1265 in participants with hemophilia B.
Part 2A and LTFU Period: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B.

Part 2A: To assess the bleeding event rate for bleeding events that require treatment with FIX replacement therapy following a single IV administration of REGV131-LNP1265 at the RDE.
Part 2A and LTFU Period: To evaluate FIX replacement therapy use following a single IV administration of REGV131-LNP1265 at the RDE, excluding FIX replacement for invasive procedures
Parts 1 and 2A: To characterize the concentration-time profile of REGV131-LNP1265
Parts 1 and 2A: To assess humoral immunogenicity of REGV131- LNP1265 following a single IV administration.
Parts 1 and 2A: To assess vector shedding after a single IV administration of REGV131-LNP1265.

Variables de Evaluación Secundaria

Part 1: Change from baseline in FIX functional activity in plasma after REGV131-LNP1265 dosing at the RDE, measured using the chromogenic substrate assay.
Part 1 and LTFU Period: ABR following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving the RDE.
Part 1, Part 2A and LTFU Period: FIX functional activity in plasma over time during the study period using the chromogenic substrate assay (up to 10 years).
Part 1 and Part 2A: Annualized treated Bleeding Rate (tABR) following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving the RDE.
Part 1, Part 2A and LTFU Period: Annualized utilization (IU/kg/year) of FIX replacement therapy following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving the RDE.
Part 1 and Part 2A: Remaining free of FIX replacement therapy among those receiving the RDE following sustained FIX expression (post-REGV131-LNP1265 dosing).
Part 1 and Part 2A: Remaining zero spontaneous bleeding events among those receiving the RDE over sustained FIX functional activity period.IX functional activity period (post-REGV131-LNP1265 dosing).
Part 1 and Part 2A: Concentrations of REGV131 components.
Part 1 and Part 2A: Concentrations of LNP1265 components.
Part 1 and Part 2A: Detection of antibodies to the Coagulation Factor IX gene (F9) transgene product FIX protein.
Part 1 and Part 2A: Detection of Total binding Antibodies (TAbs) to the Adeno-Associated Virus 8 (AAV8) capsid proteins.
Part 1 and Part 2A: Detection of Neutralizing Antibodies/Transduction Inhibitors (NAb/TI) to the AAV8 capsid proteins.
Part 1 and Part 2A: Detection of antibodies to LNP1265.
Part 1 and Part 2A: Detection of antibodies to CRISPR-associated protein 9 (Cas9) protein.
Part 1: Detection of vector DeoxyriboNucleic Acid (DNA) in blood, saliva, nasal secretions, semen, urine, and feces over time (Part 1 dose confirmation cohort only)
Part 2A: Occurrence and severity of TEAEs.
Part 2A: Detection of vector DNA in relevant matrices based on data analysis of Part 1 Dose Confirmation Cohort.
LTFU Period: Proportion of participants with zero spontaneous bleeding events following sustained FIX functional activity among those receiving RDE.
LTFU Period: Proportion of participants not requiring FIX replacement therapy following sustained FIX functional activity among those receiving RDE.

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Male gender at birth and 18 years of age. Confirmed diagnosis of severe or moderately severe hemophilia B with

medical history of FIX functional activity (2% or <0.02 IU/mL) or documented genotype known to produce severe hemophilia B. Currently taking FIX prophylaxis and previous experience with FIX therapy, as defined in the protocol. Participation in the lead-in period of this interventional study OR a separate lead-in study (R0000-HEMB-2187 [NCT05568459]) for at least 6 months for ABR data while taking FIX prophylaxis, as defined in the protocol. NOTE: Other Inclusion Protocol Defined Criteria Apply.

Criterios de Exclusión

History of FIX inhibitor (clinical or laboratory-based assessment) on 2 or more occasions.
NOTE: Other Inclusion/Exclusion Protocol Defined Criteria Apply
Bethesda inhibitor titer greater than the Upper Limit of Normal (ULN) at screening.
Detectable pre-existing antibodies to the AAV8 capsid; as measured by Enzyme-Linked ImmunoSorbent Assay (ELISA) at prescreening (or final lead-in visit [L-Final], if applicable)
Any significant underlying liver disease such as: cholestatic liver disease, liver cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy.
Evidence of advanced liver fibrosis or significant fatty liver, as defined in the protocol.
Evidence of cirrhosis and/or portal hypertension as assessed by abdominal ultrasound at screening or measured within 6 months prior to the screening visit.
History of arterial or venous thrombo-embolic events, as defined in the protocol.
History of hypersensitivity to corticosteroids or known medical condition that requires chronic administration of corticosteroids.
Previously received any AAV gene-based therapy or intends to receive approved or investigational AAV-based gene therapy other than REGV131-LNP1265 during the study period.

Calendario

(Última actualización: 22/07/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
30/09/2024	16/07/2025	10/09/2025	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
No aportado	No aportado	No aportado	No aportado	No aportado

Promotor

Regeneron Pharmaceuticals Inc. United States

777 Old Saw Mill River Road

Contact Person

Medical Affairs

+353818882469

medical.information_EU@regeneron.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Parc de Salut Mar

Doctor Aiguader, 88 Edificio PRBB 08003 Barcelona

ceic-psmar@researchmar.net

933160679

Centros

No iniciado (--/--/----)

Complexo Hospitalario Universitario A Coruna

A Coruna

CORUÑA

Hematology

No iniciado (--/--/----)

Hospital Universitari Vall D Hebron

Barcelona

BARCELONA

Hematology

No iniciado (--/--/----)

Hospital Universitario Central De Asturias

Oviedo

ASTURIAS

Hematology

No iniciado (--/--/----)

Hospital Universitario La Paz

Madrid

MADRID

Hematology

No iniciado (--/--/----)

Hospital Universitario Miguel Servet

Zaragoza

ZARAGOZA

Hematology

No iniciado (--/--/----)

Hospital Universitario Y Politecnico La Fe

Valencia

VALENCIA

Hematology

No iniciado (--/--/----)

University Clinical Hospital Virgen De La Arrixaca

Murcia

MURCIA

Hematology

No iniciado (--/--/----)

University Hospital Virgen Del Rocio S.L.

Sevilla

SEVILLA

Hematology

Medicamentos

REGV131
SOLUTION FOR INFUSION
IV INFUSION

-

Principios Activos: N/A

Experimental

LNP1265
SOLUTION FOR INFUSION
IV INFUSION

-

Principios Activos: N/A

Experimental

Sin resultados

A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Adult Patients with Hemophilia B

State	**Type of participants**	**Age Ranges**
Recruiting	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Men	Phase I , Phase II	78
Results	**Low level of intervention**	**Rare disease**
No results	No	Yes
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	safety, effectiveness	Gene therapy

Information

Identifier
2023-507260-40-00 (CTIS)

Protocol Code
R131L1265-HEMB-2318

Therapeutic area
Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]|

Investigated Disease
Hemophilia B

Scientific Title
A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B

Rationale

Not provided

Main Objective

Part 1: To evaluate the safety and tolerability of a single IV administration of REGV131-LNP1265 in participants with hemophilia B.
To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B to establish the recommended dose for further development
Part 2A: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B receiving the recommended dose for expansion (RDE). To assess the bleeding event rate (all bleeding events) following a single IV administration of REGV131-LNP1265 at the RDE
Long-term Follow Up (LTFU) Period: To evaluate the long-term safety of a single IV administration of REGV131-LNP1265 in participants with hemophilia B

Primary Endpoints

Part 1: Occurrence and severity of Treatment-Emergent Adverse Events (TEAEs).
Part 1: Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assay.
Part 2A: Change from baseline in FIX functional activity in plasma after REGV131-LNP1265 dosing at the recommended dose for expansion (RDE) measured using the chromogenic substrate assay.
Part 2A: Annualized Bleeding Rate (ABR) following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving RDE.
LTFU Period: Occurrence and severity of Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and clinically meaningful Adverse Events (AEs).

Temporary moments of secondary assessment

Not provided

Secondary Objective

Part 1: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B receiving the RDE.
Part 1 and LTFU Period: To assess the bleeding event rate (all bleeding events) following a single IV administration of REGV131-LNP1265 at the RDE.
Part 1 and LTFU Period: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B
Part 1: To assess the bleeding event rate for bleeding events that require treatment with FIX replacement therapy following a single IV administration of REGV131-LNP1265 at the RDE.
Part 1 and LTFU Period: To evaluate FIX replacement therapy use following a single IV administration of REGV131-LNP1265 at the RDE, excluding FIX replacement for invasive procedures
Part 2A: To evaluate the safety and tolerability of a single IV administration of REGV131-LNP1265 in participants with hemophilia B.
Part 2A and LTFU Period: To evaluate clotting FIX functional activity following a single IV administration of REGV131-LNP1265 in participants with hemophilia B.

Part 2A: To assess the bleeding event rate for bleeding events that require treatment with FIX replacement therapy following a single IV administration of REGV131-LNP1265 at the RDE.
Part 2A and LTFU Period: To evaluate FIX replacement therapy use following a single IV administration of REGV131-LNP1265 at the RDE, excluding FIX replacement for invasive procedures
Parts 1 and 2A: To characterize the concentration-time profile of REGV131-LNP1265
Parts 1 and 2A: To assess humoral immunogenicity of REGV131- LNP1265 following a single IV administration.
Parts 1 and 2A: To assess vector shedding after a single IV administration of REGV131-LNP1265.

Secondary Endpoints

Part 1: Change from baseline in FIX functional activity in plasma after REGV131-LNP1265 dosing at the RDE, measured using the chromogenic substrate assay.
Part 1 and LTFU Period: ABR following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving the RDE.
Part 1, Part 2A and LTFU Period: FIX functional activity in plasma over time during the study period using the chromogenic substrate assay (up to 10 years).
Part 1 and Part 2A: Annualized treated Bleeding Rate (tABR) following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving the RDE.
Part 1, Part 2A and LTFU Period: Annualized utilization (IU/kg/year) of FIX replacement therapy following sustained FIX functional activity (post-REGV131-LNP1265 dosing) among participants receiving the RDE.
Part 1 and Part 2A: Remaining free of FIX replacement therapy among those receiving the RDE following sustained FIX expression (post-REGV131-LNP1265 dosing).
Part 1 and Part 2A: Remaining zero spontaneous bleeding events among those receiving the RDE over sustained FIX functional activity period.IX functional activity period (post-REGV131-LNP1265 dosing).
Part 1 and Part 2A: Concentrations of REGV131 components.
Part 1 and Part 2A: Concentrations of LNP1265 components.
Part 1 and Part 2A: Detection of antibodies to the Coagulation Factor IX gene (F9) transgene product FIX protein.
Part 1 and Part 2A: Detection of Total binding Antibodies (TAbs) to the Adeno-Associated Virus 8 (AAV8) capsid proteins.
Part 1 and Part 2A: Detection of Neutralizing Antibodies/Transduction Inhibitors (NAb/TI) to the AAV8 capsid proteins.
Part 1 and Part 2A: Detection of antibodies to LNP1265.
Part 1 and Part 2A: Detection of antibodies to CRISPR-associated protein 9 (Cas9) protein.
Part 1: Detection of vector DeoxyriboNucleic Acid (DNA) in blood, saliva, nasal secretions, semen, urine, and feces over time (Part 1 dose confirmation cohort only)
Part 2A: Occurrence and severity of TEAEs.
Part 2A: Detection of vector DNA in relevant matrices based on data analysis of Part 1 Dose Confirmation Cohort.
LTFU Period: Proportion of participants with zero spontaneous bleeding events following sustained FIX functional activity among those receiving RDE.
LTFU Period: Proportion of participants not requiring FIX replacement therapy following sustained FIX functional activity among those receiving RDE.

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Male gender at birth and 18 years of age. Confirmed diagnosis of severe or moderately severe hemophilia B with

medical history of FIX functional activity (2% or <0.02 IU/mL) or documented genotype known to produce severe hemophilia B. Currently taking FIX prophylaxis and previous experience with FIX therapy, as defined in the protocol. Participation in the lead-in period of this interventional study OR a separate lead-in study (R0000-HEMB-2187 [NCT05568459]) for at least 6 months for ABR data while taking FIX prophylaxis, as defined in the protocol. NOTE: Other Inclusion Protocol Defined Criteria Apply.

Exclusion criteria

History of FIX inhibitor (clinical or laboratory-based assessment) on 2 or more occasions.
NOTE: Other Inclusion/Exclusion Protocol Defined Criteria Apply
Bethesda inhibitor titer greater than the Upper Limit of Normal (ULN) at screening.
Detectable pre-existing antibodies to the AAV8 capsid; as measured by Enzyme-Linked ImmunoSorbent Assay (ELISA) at prescreening (or final lead-in visit [L-Final], if applicable)
Any significant underlying liver disease such as: cholestatic liver disease, liver cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy.
Evidence of advanced liver fibrosis or significant fatty liver, as defined in the protocol.
Evidence of cirrhosis and/or portal hypertension as assessed by abdominal ultrasound at screening or measured within 6 months prior to the screening visit.
History of arterial or venous thrombo-embolic events, as defined in the protocol.
History of hypersensitivity to corticosteroids or known medical condition that requires chronic administration of corticosteroids.
Previously received any AAV gene-based therapy or intends to receive approved or investigational AAV-based gene therapy other than REGV131-LNP1265 during the study period.

Calendar

(Last Update: 22/07/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
30/09/2024	16/07/2025	10/09/2025	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
Not aported	Not aported	Not aported	Not aported	Not aported

Sponsor

Regeneron Pharmaceuticals Inc. United States

777 Old Saw Mill River Road

Contact Person

Medical Affairs

+353818882469

medical.information_EU@regeneron.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Parc de Salut Mar

Doctor Aiguader, 88 Edificio PRBB 08003 Barcelona

ceic-psmar@researchmar.net

933160679

Sites

not initialized (--/--/----)

Complexo Hospitalario Universitario A Coruna

A Coruna

CORUÑA

Hematology

not initialized (--/--/----)

Hospital Universitari Vall D Hebron

Barcelona

BARCELONA

Hematology

not initialized (--/--/----)

Hospital Universitario Central De Asturias

Oviedo

ASTURIAS

Hematology

not initialized (--/--/----)

Hospital Universitario La Paz

Madrid

MADRID

Hematology

not initialized (--/--/----)

Hospital Universitario Miguel Servet

Zaragoza

ZARAGOZA

Hematology

not initialized (--/--/----)

Hospital Universitario Y Politecnico La Fe

Valencia

VALENCIA

Hematology

not initialized (--/--/----)

University Clinical Hospital Virgen De La Arrixaca

Murcia

MURCIA

Hematology

not initialized (--/--/----)

University Hospital Virgen Del Rocio S.L.

Sevilla

SEVILLA

Hematology

Medication

REGV131
SOLUTION FOR INFUSION
IV INFUSION

-

Active Principles: N/A

Experimental

LNP1265
SOLUTION FOR INFUSION
IV INFUSION

-

Active Principles: N/A

Experimental

No results